ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Molecular characterization of extended-spectrum β-lactamases-producing Escherichia coli isolated from patients with bacteremia.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteremia is a major health problem that affects millions of people worldwide. E. coli is one of the main pathogens associated with bacteremia and its resistance to the antimicrobial drugs, including β-lactams, has significantly increased in recent years. In view of the above, our objective was to determine the antimicrobial resistance profile of 60 E. coli isolates obtained from patients with bacteremia, as well as to characterize extended-spectrum β-lactamases (ESBL) -producing isolates. The highest resistance rates were observed for ciprofloxacin (33.3%), levofloxacin (31.7%), cefuroxime (20%) and cefotaxime (20%). Furthermore, 12 isolates (20%) were ESBL producers. Genomic analysis showed that 58.3% of these ESBL-producing isolates belonged to the phylogroup B2, ST131, serotype O25:H4 and carried the following ESBL-encoding genes: bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.